11月份144只普通股基上涨 富国医药创新股票等领涨

Core Insights - In November, out of 1,046 comparable ordinary equity funds, only 144 funds achieved positive performance, while 902 funds experienced declines [1][2]. Group 1: Top Performing Funds - The top-performing funds in November included Manulife High-End Equipment Stock A (4.90%), Manulife High-End Equipment Stock C (4.86%), and Anxin Cycle Preferred Stock A (4.18%) [1][2]. - The Anxin Cycle Preferred Stock has maintained a strong focus on mining stocks, with a year-to-date performance increase exceeding 50% [2]. - The Fortune Medical Innovation Stock, primarily invested in pharmaceutical stocks, has seen a remarkable year-to-date increase of 90% due to the surge in Hong Kong pharmaceutical stocks [2][3]. Group 2: Fund Management Background - The fund manager of Manulife High-End Equipment Stock, Meng Jie, has over five years of experience managing public funds and has been with Manulife since July 2015 [1]. - The Anxin Cycle Preferred Stock is managed by a team with a strong focus on mining and new energy materials, contributing to its significant performance this year [2]. - Fortune Medical Innovation Stock is managed by Zhao Wei, who has over eight years of experience in fund management and has been with Fortune since March 2021 [2]. Group 3: Underperforming Funds - In November, 12 ordinary equity funds recorded declines exceeding 8%, with notable losses from Taikang Medical Health Stock A and C, which fell by 9.40% and 9.36% respectively [3][4]. - HSBC Jintrust Low Carbon Pioneer Stock C and A also experienced declines of 8.98% and 8.94%, respectively, due to their heavy investments in the downstream segments of the new energy sector [4]. - The Caixin Integrated Circuit Industry Stock faced a decline of 8.7% in November after a previous increase in October, reflecting a significant pullback in semiconductor stocks [4].